Subtopic Deep Dive

Mast Cells in Allergic Diseases
Research Guide

What is Mast Cells in Allergic Diseases?

Mast cells in allergic diseases refers to the role of mast cells in initiating and propagating IgE-mediated inflammatory responses in conditions such as asthma, anaphylaxis, and atopic dermatitis.

Mast cells degranulate upon high-affinity IgE receptor (FcεRI) crosslinking, releasing histamine, prostaglandins, and cytokines that drive allergic inflammation (Galli and Tsai, 2012, 1709 citations). Key mediators include prostaglandin D2 (PGD2), which recruits Th2 cells, eosinophils, and basophils via the CRTH2 receptor (Hirai et al., 2001, 1080 citations). Over 10 high-citation papers document mast cell contributions to airway hyperresponsiveness and eosinophil infiltration in asthma (Wills-Karp, 1999, 1027 citations).

Curated Papers

Key Challenges

Why It Matters

Mast cell-targeted therapies like omalizumab block IgE-FcεRI interactions, reducing anaphylaxis and asthma exacerbations in clinical practice (Galli and Tsai, 2012). PGD2-CRTH2 antagonists show promise in attenuating Th2 cell chemotaxis and eosinophil recruitment in atopic diseases (Hirai et al., 2001; Matsuoka et al., 2000, 736 citations). These insights enable precision medicine for the global rise in allergic conditions, with mast cell stabilizers informing treatments for 300 million asthma patients worldwide (Galli et al., 2008, 1756 citations; Amin, 2011).

Key Research Challenges

Heterogeneity of Mast Cell Subtypes

Mast cells exhibit connective tissue and mucosal subtypes with distinct mediator profiles, complicating targeted therapies in heterogeneous diseases like asthma (Krystel-Whittemore et al., 2016, 855 citations). Phenotypic plasticity alters responses to allergens across tissues (Galli and Tsai, 2012). This variability challenges uniform biologic interventions.

Downstream Mediator Complexity

Beyond histamine, PGD2 acts via DP and CRTH2 receptors to sustain Th2 inflammation, while interactions with eosinophils and T cells amplify hyperresponsiveness (Matsuoka et al., 2000; Hirai et al., 2001). Balancing inhibition risks off-target effects on protective immunity (Turner and Kinet, 1999, 729 citations). Dissecting cascades remains difficult.

Translating Models to Humans

Murine models replicate IgE-mast cell degranulation but diverge in chronic human asthma pathology, including persistent eosinophilia (Bradley et al., 1991, 673 citations; Wills-Karp, 1999). Clinical trials struggle with biomarkers for mast cell activation (Amin, 2011). Bridging species gaps hinders drug development.

Essential Papers

The development of allergic inflammation

Stephen J. Galli, Mindy Tsai, Adrian M. Piliponsky · 2008 · Nature · 1.8K citations

IgE and mast cells in allergic disease

Stephen J. Galli, Mindy Tsai · 2012 · Nature Medicine · 1.7K citations

Prostaglandin D2 Selectively Induces Chemotaxis in T Helper Type 2 Cells, Eosinophils, and Basophils via Seven-Transmembrane Receptor Crth2

Hiroyuki Hirai, Kazuya Tanaka, Osamu Yoshie et al. · 2001 · The Journal of Experimental Medicine · 1.1K citations

Prostaglandin (PG)D2, which has long been implicated in allergic diseases, is currently considered to elicit its biological actions through the DP receptor (DP). Involvement of DP in the formation ...

IMMUNOLOGIC BASIS OF ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESS

Marsha Wills‐Karp · 1999 · Annual Review of Immunology · 1.0K citations

▪ Abstract The incidence, morbidity, and mortality of asthma has increased worldwide over the last two decades. Asthma is a complex inflammatory disease of the lung characterized by variable airflo...

Mast Cell: A Multi-Functional Master Cell

Melissa Krystel‐Whittemore, Kottarappat N. Dileepan, John G. Wood · 2016 · Frontiers in Immunology · 855 citations

Mast cells are immune cells of the myeloid lineage and are present in connective tissues throughout the body. The activation and degranulation of mast cells significantly modulates many aspects of ...

Prostaglandin D <sub>2</sub> as a Mediator of Allergic Asthma

Toshiyuki Matsuoka, Masakazu Hirata, Hiroyuki Tanaka et al. · 2000 · Science · 736 citations

Allergic asthma is caused by the aberrant expansion in the lung of T helper cells that produce type 2 (T H 2) cytokines and is characterized by infiltration of eosinophils and bronchial hyperreacti...

Signalling through the high-affinity IgE receptor FcεRI

Helen Turner, Jean-Pierre Kinet · 1999 · Nature · 729 citations

Reading Guide

Foundational Papers

Start with Galli et al. (2008, 1756 citations) for allergic inflammation overview and Galli and Tsai (2012, 1709 citations) for IgE-mast cell mechanisms, as they anchor 80% of subsequent citations. Add Wills-Karp (1999, 1027 citations) for airway hyperresponsiveness basis.

Recent Advances

Study Krystel-Whittemore et al. (2016, 855 citations) for mast cell multifunctionality updates and Amin (2011, 630 citations) for inflammation roles, bridging to clinical translation.

Core Methods

Core techniques include FcεRI signaling assays (Turner and Kinet, 1999), PGD2-CRTH2 chemotaxis (Hirai et al., 2001), and biopsy immunohistochemistry for cell infiltration (Bradley et al., 1991).

How PapersFlow Helps You Research Mast Cells in Allergic Diseases

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map the 1756-citation Galli et al. (2008) paper's influence, revealing clusters around IgE-mast cell pathways in asthma, then exaSearch uncovers omalizumab trials linked to it.

Analyze & Verify

Analysis Agent employs readPaperContent on Hirai et al. (2001) to extract CRTH2-PGD2 chemotaxis data, verifies claims via CoVe against Wills-Karp (1999), and runs PythonAnalysis to plot eosinophil recruitment stats with GRADE scoring for evidence strength in Th2 models.

Synthesize & Write

Synthesis Agent detects gaps in PGD2 therapeutics post-Matsuoka et al. (2000), flags contradictions between mouse and human data from Bradley et al. (1991); Writing Agent uses latexEditText, latexSyncCitations for Galli papers, and latexCompile to generate review sections with exportMermaid diagrams of FcεRI signaling.

Use Cases

"Analyze PGD2 mast cell pathways in human vs mouse asthma models"

Research Agent → searchPapers('PGD2 mast cells asthma') → Analysis Agent → readPaperContent(Matsuoka 2000) + runPythonAnalysis(pandas correlation of citations vs model type) → GRADE-verified comparison table showing 80% pathway overlap.

"Draft LaTeX review on IgE-mast cell degranulation in anaphylaxis"

Synthesis Agent → gap detection(Galli 2012) → Writing Agent → latexEditText('add FcεRI section') → latexSyncCitations([Galli2012,Tsai2012,Turner1999]) → latexCompile → PDF with 3 figures on degranulation cascades.

"Find code for simulating mast cell histamine release kinetics"

Research Agent → paperExtractUrls(Galli2008) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python sandbox with ODE solver code outputting histamine time-series plots validated against Krystel-Whittemore (2016).

Automated Workflows

Deep Research workflow scans 50+ papers from Galli/Tsai cluster via citationGraph, producing a structured report on mast cell-IgE evolution in allergies with GRADE tables. DeepScan applies 7-step CoVe to verify PGD2 claims across Hirai (2001) and Matsuoka (2000), checkpointing eosinophil data fidelity. Theorizer generates hypotheses on CRTH2 blockade efficacy by synthesizing Wills-Karp (1999) hyperresponsiveness mechanisms.

Try Doxa for Mast Cells in Allergic Diseases Research

Frequently Asked Questions

What defines mast cell role in allergic diseases?

Mast cells drive IgE-FcεRI mediated degranulation releasing histamine and PGD2, initiating Th2 inflammation in asthma and anaphylaxis (Galli and Tsai, 2012).

What are key methods to study mast cell activation?

FcεRI crosslinking assays and CRTH2 chemotaxis models assess degranulation and recruitment (Turner and Kinet, 1999; Hirai et al., 2001). Bronchial biopsies quantify mast cell-eosinophil proximity (Bradley et al., 1991).

What are seminal papers?

Galli et al. (2008, 1756 citations) on allergic inflammation development; Galli and Tsai (2012, 1709 citations) on IgE-mast cells; Matsuoka et al. (2000, 736 citations) on PGD2 in asthma.

What open problems exist?

Resolving mast cell plasticity across subtypes and translating PGD2 inhibitors from mice to humans with reliable biomarkers (Krystel-Whittemore et al., 2016; Amin, 2011).